Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy, as neoadjuvant therapy for patients with HER2-positive breast cancer.
Pertuzumab
BO22280
NCT00976989
malignant neoplasm of breast
Phase 2
 
October 2016

Powered by ideaPoint, Inc.